Morepen Laboratories (NSE:MOREPENLAB) Cash-to-Debt : N/A (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Morepen Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Morepen Laboratories's cash to debt ratio for the quarter that ended in Dec. 2023 was N/A.

The historical rank and industry rank for Morepen Laboratories's Cash-to-Debt or its related term are showing as below:

NSE:MOREPENLAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.94 Max: 12.06
Current: 2.32

During the past 13 years, Morepen Laboratories's highest Cash to Debt Ratio was 12.06. The lowest was 0.05. And the median was 0.94.

NSE:MOREPENLAB's Cash-to-Debt is ranked better than
62.81% of 1046 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs NSE:MOREPENLAB: 2.32

Morepen Laboratories Cash-to-Debt Historical Data

The historical data trend for Morepen Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Morepen Laboratories Cash-to-Debt Chart

Morepen Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.81

1.01

2.43

0.85

0.86

Morepen Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															N/A	0.86	N/A	2.32	N/A

Competitive Comparison of Morepen Laboratories's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Morepen Laboratories's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Cash-to-Debt falls into.

Morepen Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Morepen Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	216.658	/	(242.306	+	9.335)
	=	0.86

Morepen Laboratories's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Morepen Laboratories (NSE:MOREPENLAB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Morepen Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Morepen Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Morepen Laboratories (NSE:MOREPENLAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Morepen Laboratories Ltd (NSE:MOREPENLAB) » Definitions » Cash-to-Debt

Traded in Other Exchanges

500288:India

Address

2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector 20, Gurugram, HR, IND, 122016

Website

https://www.morepen.com

Morepen Laboratories Ltd is an India based pharmaceutical company. It develops, manufactures and markets generic drugs and pharmaceutical formulations. The company's products includes Tablets, Capsules, Injections, Ointments, Syrups, and Powders. It also offers products under brands Burnol, Lemolate and Fiber-X. The company's geographical markets include India, the United States and the rest of the world, with a majority of revenue being generated in India.

Morepen Laboratories (NSE:MOREPENLAB) Headlines

No Headlines